Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: Nitric Oxide (NO) Releasing Materials for Use in Medical Devices Related to Microbial Management and Wound Care, 27885 [2014-11145]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 94 / Thursday, May 15, 2014 / Notices
Contact Person: Martha Garcia, Ph.D.,
Scientific Reviewer Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2186,
MSC 7818, Bethesda, MD 20892, 301–435–
1243, garciamc@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research; 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: May 8, 2014.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–11133 Filed 5–14–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up
Exclusive Evaluation Option License
Agreement: Nitric Oxide (NO)
Releasing Materials for Use in Medical
Devices Related to Microbial
Management and Wound Care
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of a
Start-Up Exclusive Evaluation Option
License Agreement to iFyber LLC, a
company having a place of business in
Ithaca, New York to practice the
inventions embodied in the following
patent applications and patents:
TKELLEY on DSK3SPTVN1PROD with NOTICES
SUMMARY:
1. U.S. Patent 7,968,664, issued June 28,
2011, titled ‘‘Nitric Oxide Releasing
Diazeniumdiolated Acrylonitrile-Based
Polymers, And Compositions, Medical
Devices, And Uses Thereof’’ [HHS Ref.
No. E–188–2004/0–US–06];
2. U.S. Patent 8,093,343, issued January 10,
2012, titled ‘‘Nitric Oxide-Releasing
Diazeniumdiolated Compounds’’ [HHS
Ref. No. E–188–2004/0–US–08];
3. European Patent Application 05802080.1,
filed September 27, 2005, titled ‘‘Nitric
Oxide Releasing Diazeniumdiolated
Acrylonitrile-Based Polymers, And
Compositions, Medical Devices, And
Uses Thereof’’ [HHS Ref. No. E–188–
2004/0–EP–05];
4. Canadian Patent 2581939, issued January
8, 2013, titled ‘‘Nitric Oxide Releasing
Diazeniumdiolated Acrylonitrile-Based
Polymers, And Compositions, Medical
Devices, And Uses Thereof’’ [HHS Ref.
No. E–188–2004/0–CA–04];
5. Australian Patent Application 2005289414,
filed September 27, 2005, titled ‘‘Nitric
VerDate Mar<15>2010
18:18 May 14, 2014
Jkt 232001
Oxide Releasing Diazeniumdiolated
Acrylonitrile-Based Polymers, And
Compositions, Medical Devices, And
Uses Thereof’’ [HHS Ref. No. E–188–
2004/0–AU–03]; and
6. Australian Patent 2011200972, issued July
5, 2012, titled ‘‘Nitric Oxide-Releasing
Compounds and Uses Thereof’’ [HHS
Ref. No. E–188–2004/0–AU–07]
The patent rights in these inventions
have been assigned to the Government
of the United States of America. The
territory of the prospective Start-up
Exclusive Evaluation Option License
Agreement may be worldwide, and the
field of use may be limited to: ‘‘Nitric
oxide (NO) releasing materials for use in
medical/surgical tubing and attachment
devices related to tubing; and wound
healing devices, including wound
dressings/bandages.’’
Upon the expiration or termination of
the Start-up Exclusive Evaluation
Option License Agreement, iFyber will
have the exclusive right to execute a
Start-up Exclusive Patent License
Agreement which will supersede and
replace the Start-up Exclusive
Evaluation Option License Agreement,
with no greater field of use and territory
than granted in the Start-up Exclusive
Evaluation Option License Agreement.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before May
30, 2014 will be considered.
ADDRESSES: Requests for copies of the
patents, patent applications, inquiries,
comments, and other materials relating
to the contemplated Start-Up Exclusive
Evaluation Option License Agreement
should be directed to: Betty B. Tong,
Ph.D., Senior Licensing and Patenting
Manager, Office of Technology Transfer,
National Institutes of Health, 6011
Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Telephone:
(301) 594–6565; Facsimile: (301) 402–
0220; Email: tongb@mail.nih.gov. A
signed confidentiality nondisclosure
agreement will be required to receive
copies of any patent applications that
have not been published or issued by
the United States Patent and Trademark
Office or the World Intellectual Property
Organization.
SUPPLEMENTARY INFORMATION: The
subject invention describes a family of
polymers based on poly(acrylonitrile)
that are capable of storing Nitric oxide
(NO) bound in a stable chemical
functionality, called a diazeniumdiolate
group, and releasing NO under aqueous
conditions. The incorporation of these
NO-releasing diazeniumdiolated
acrylonitrile-based compositions into
suitable, biocompatible dressings could
be used to treat wounds to fight
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
27885
infection, modulate inflammation, and
promote angiogenesis and collagen
synthesis in order to accelerate wound
closure and/or otherwise improve
functional outcomes. These
polyacrylonitrile-based products could
be useful in conjunction with medical
devices where the many therapeutic
actions of NO would be beneficial.
The prospective Start-up Exclusive
Evaluation Option License Agreement
and a subsequent Start-up Exclusive
Patent License Agreement may be
granted unless the NIH receives written
evidence and argument, within fifteen
(15) days from the date of this published
notice, that establishes that the grant of
the contemplated Start-up Exclusive
Evaluation Option License Agreement
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Start-Up Exclusive
Evaluation Option License Agreement.
Comments and objections submitted in
response to this notice will not be made
available for public inspection and, to
the extent permitted by law, will not be
released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: May 12, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2014–11145 Filed 5–14–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[USCG–2013–1073]
Collection of Information Under
Review by Office of Management and
Budget
Coast Guard, DHS.
Thirty-day notice requesting
comments.
AGENCY:
ACTION:
In compliance with the
Paperwork Reduction Act of 1995 the
U.S. Coast Guard is forwarding
Information Collection Requests (ICRs),
abstracted below, to the Office of
Management and Budget (OMB), Office
of Information and Regulatory Affairs
(OIRA), requesting approval of a
Revision to the following collections of
information: 1625–0017, Various
International Agreement Safety
SUMMARY:
E:\FR\FM\15MYN1.SGM
15MYN1
]]>Agencies
[Federal Register Volume 79, Number 94 (Thursday, May 15, 2014)]
[Notices]
[Page 27885]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-11145]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up Exclusive Evaluation Option License
Agreement: Nitric Oxide (NO) Releasing Materials for Use in Medical
Devices Related to Microbial Management and Wound Care
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
part 404, that the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of a Start-Up Exclusive
Evaluation Option License Agreement to iFyber LLC, a company having a
place of business in Ithaca, New York to practice the inventions
embodied in the following patent applications and patents:
1. U.S. Patent 7,968,664, issued June 28, 2011, titled ``Nitric
Oxide Releasing Diazeniumdiolated Acrylonitrile-Based Polymers, And
Compositions, Medical Devices, And Uses Thereof'' [HHS Ref. No. E-
188-2004/0-US-06];
2. U.S. Patent 8,093,343, issued January 10, 2012, titled ``Nitric
Oxide-Releasing Diazeniumdiolated Compounds'' [HHS Ref. No. E-188-
2004/0-US-08];
3. European Patent Application 05802080.1, filed September 27, 2005,
titled ``Nitric Oxide Releasing Diazeniumdiolated Acrylonitrile-
Based Polymers, And Compositions, Medical Devices, And Uses
Thereof'' [HHS Ref. No. E-188-2004/0-EP-05];
4. Canadian Patent 2581939, issued January 8, 2013, titled ``Nitric
Oxide Releasing Diazeniumdiolated Acrylonitrile-Based Polymers, And
Compositions, Medical Devices, And Uses Thereof'' [HHS Ref. No. E-
188-2004/0-CA-04];
5. Australian Patent Application 2005289414, filed September 27,
2005, titled ``Nitric Oxide Releasing Diazeniumdiolated
Acrylonitrile-Based Polymers, And Compositions, Medical Devices, And
Uses Thereof'' [HHS Ref. No. E-188-2004/0-AU-03]; and
6. Australian Patent 2011200972, issued July 5, 2012, titled
``Nitric Oxide-Releasing Compounds and Uses Thereof'' [HHS Ref. No.
E-188-2004/0-AU-07]
The patent rights in these inventions have been assigned to the
Government of the United States of America. The territory of the
prospective Start-up Exclusive Evaluation Option License Agreement may
be worldwide, and the field of use may be limited to: ``Nitric oxide
(NO) releasing materials for use in medical/surgical tubing and
attachment devices related to tubing; and wound healing devices,
including wound dressings/bandages.''
Upon the expiration or termination of the Start-up Exclusive
Evaluation Option License Agreement, iFyber will have the exclusive
right to execute a Start-up Exclusive Patent License Agreement which
will supersede and replace the Start-up Exclusive Evaluation Option
License Agreement, with no greater field of use and territory than
granted in the Start-up Exclusive Evaluation Option License Agreement.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before May
30, 2014 will be considered.
ADDRESSES: Requests for copies of the patents, patent applications,
inquiries, comments, and other materials relating to the contemplated
Start-Up Exclusive Evaluation Option License Agreement should be
directed to: Betty B. Tong, Ph.D., Senior Licensing and Patenting
Manager, Office of Technology Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804;
Telephone: (301) 594-6565; Facsimile: (301) 402-0220; Email:
tongb@mail.nih.gov. A signed confidentiality nondisclosure agreement
will be required to receive copies of any patent applications that have
not been published or issued by the United States Patent and Trademark
Office or the World Intellectual Property Organization.
SUPPLEMENTARY INFORMATION: The subject invention describes a family of
polymers based on poly(acrylonitrile) that are capable of storing
Nitric oxide (NO) bound in a stable chemical functionality, called a
diazeniumdiolate group, and releasing NO under aqueous conditions. The
incorporation of these NO-releasing diazeniumdiolated acrylonitrile-
based compositions into suitable, biocompatible dressings could be used
to treat wounds to fight infection, modulate inflammation, and promote
angiogenesis and collagen synthesis in order to accelerate wound
closure and/or otherwise improve functional outcomes. These
polyacrylonitrile-based products could be useful in conjunction with
medical devices where the many therapeutic actions of NO would be
beneficial.
The prospective Start-up Exclusive Evaluation Option License
Agreement and a subsequent Start-up Exclusive Patent License Agreement
may be granted unless the NIH receives written evidence and argument,
within fifteen (15) days from the date of this published notice, that
establishes that the grant of the contemplated Start-up Exclusive
Evaluation Option License Agreement would not be consistent with the
requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the prospective field of use
that are filed in response to this notice will be treated as objections
to the grant of the contemplated Start-Up Exclusive Evaluation Option
License Agreement. Comments and objections submitted in response to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: May 12, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-11145 Filed 5-14-14; 8:45 am]
BILLING CODE 4140-01-P
